Belite Bio (BLTE) Other Non-Current Assets (2021 - 2026)
Belite Bio (BLTE) posted quarterly Other Non-Current Assets of $289.4 million for Q1 2026, up 5789.44% year-over-year from $4.9 million in Q1 2025, and up 1.09% quarter-over-quarter from $286.3 million in Q4 2025.
Belite Bio (BLTE) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Belite Bio's Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $289.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 5789.44% year-over-year to $289.4 million; the TTM figure through Mar 2026 stood at $289.4 million (up 5789.44% YoY), while the FY2025 annual figure was $286.3 million, up 277845.63% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $289.4 million, up from $286.3 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $289.4 million in Q1 2026, with the low at $88000.0 in Q4 2022.
- The 5-year median for Other Non-Current Assets is $3.1 million (2023), against an average of $43.2 million.
- Peak annual rise in Other Non-Current Assets reached 277845.63% in 2025, while the deepest fall reached 97.78% in 2025.
- Belite Bio's Other Non-Current Assets stood at $88000.0 in 2022, then grew by 18.18% to $104000.0 in 2023, then fell by 0.96% to $103000.0 in 2024, then soared by 277845.63% to $286.3 million in 2025, then gained by 1.09% to $289.4 million in 2026.
- Business Quant data shows BLTE's Other Non-Current Assets at $289.4 million in Q1 2026, $286.3 million in Q4 2025, and $101000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 289.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 289.41 Mn |
| Dec 31, 2025 | 286.28 Mn |
| Sep 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 5.44 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | 4.55 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Mar 31, 2024 | 4.68 Mn |
| Dec 31, 2023 | 104,000.00 |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 1.56 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 88,000.00 |
| Dec 31, 2021 | 917,000.00 |